-3.3 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter' vs 'none' in 'Hoxb8-FL; MEF2A knockout' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-3.3 | | Chst12 | 'heat-shocked at 42 degreeC' vs 'grown at 33 degreeC' in 'HdhQ111 knock-in' | genotype, growth condition | Transcription profiling by array of mouse wild type and Htt mutant striatal cells upon heat shock |
3.2 | | Chst12 | 'hepatocyte-derived proliferative ducts (hepPDs)' vs 'hepatocyte' | cell type | Transcription profiling by high throughput sequencing of hepatocyte-derived progenitors cells in a mouse model of oval cell activation |
-3.1 | | Chst12 | 'lipopolysaccharide; 1 microgram per milliliter' vs 'none' in 'Nfkbiz-/-' | compound, genotype | Inhibitor of NFκB ζ (IκBζ) is a transcriptional key regulator of monocyte chemoattractant protein-1 (MCP-1/CCL2) |
-3 | | Chst12 | 'erythroblast' vs 'hematopoietic stem cell' | cell type | Transcription profiling by array of primary megakaryocytes (MEG) and erythroblasts (ERY) developed from murine fetal liver hematopoietic stem cells |
-2.9 | | Chst12 | 'LDB1 knock-down with full-length Ldb1 construct' vs 'control shRNA' | RNA interference | Role of LDB1 in the transition from chromatin looping to transcription activation |
-2.7 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar and interferon beta; 100 units per milliliter' vs 'none' in 'primary cell line; wild type genotype' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
2.7 | | Chst12 | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
2.7 | | Chst12 | '3 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-2.6 | | Chst12 | 'induced neural stem cell' vs 'mouse embryonic fibroblast cell' | cell type | Gene expression profile of mouse induced neural stem cells |
-2.4 | | Chst12 | 'germ free C57BL/6' vs 'specific pathogen free C57BL/6' in 'wild type genotype' | genotype, strain | RNA sequencing of primary isolated unstimulated murine splenic cDC from specific pathogen free (SPF), Germ Free (GF) and Interferon alpha/beta receptor 1 (Ifnar) knock out mice. |
2.4 | | Chst12 | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-2.3 | | Chst12 | 'carcinoma' vs 'normal' | disease | Gene expression profile between normal mouse skin and carcinomas arising in the skin of RbF/F;K14creERTM;p107-/- mouse |
2.3 | | Chst12 | 'Zbtb10 knockdown' vs 'control' at '2 hour' | genotype, time | RNA-seq of Zbtb10 Knockdown and Control cDC1 dendritic cells (Cd8+) |
-2.2 | | Chst12 | 'CpG; 6 hour' vs 'none; 0 hour' in 'SMRT shRNA' | RNA interference, stimulus, time | RNA-seq of Control and SMRT KD CD8α+ DCs at 0hr and 6hr CpG stimulation |
-2.2 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter' vs 'none' in 'Hoxb8-FL; wild type genotype' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-2.2 | | Chst12 | 'MG132; 1 micromolar' vs 'DMSO' in 'wild type' | compound, genotype | Microarray to find CHOP dependent genes in response to proteasome inhibition |
-2.2 | | Chst12 | 'MEF; transduced with MyoD lentivirus' vs 'MEF; control' | cell line, treatment | Genetic and epigenetic determinants of neurogenesis and myogenesis [expression profiling] |
2.2 | | Chst12 | 'interleukin-13 (Mus musculus); 10 nanogram per milliliter' vs 'none' | compound | RNAseq of small intestinal organoids from mice treated with the cytokines IFNG, IL-13 and IL-22 for 24 hours |
-2.1 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter' vs 'none' in 'primary cell line; wild type genotype' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-2.1 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar' vs 'none' in 'primary cell line; wild type genotype' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-2.1 | | Chst12 | 'SMRT shRNA; CpG; 6 hour' vs 'none; none; 0 hour' | RNA interference, stimulus, time | RNA-seq of Control and SMRT KD CD8α+ DCs at 0hr and 6hr CpG stimulation |
2 | | Chst12 | 'adipose tissue specific Cnot1 knockout' vs 'wild type phenotype' in 'brown adipose tissue' | organism part, phenotype | RNA-seq to identify the role of mRNA decay in mouse adipose tissues |
-2 | | Chst12 | 'lipopolysaccharide; 1 microgram per milliliter' vs 'none' in 'wild type' | compound, genotype | Inhibitor of NFκB ζ (IκBζ) is a transcriptional key regulator of monocyte chemoattractant protein-1 (MCP-1/CCL2) |
-2 | | Chst12 | 'heat-shocked at 42 degreeC' vs 'grown at 33 degreeC' in 'wild type' | genotype, growth condition | Transcription profiling by array of mouse wild type and Htt mutant striatal cells upon heat shock |
-1.9 | | Chst12 | 'Salmonella enterica serovar Typhimurium' vs 'control' in 'bone marrow macrophage from 129P2 mouse strain' | clinical information, infect | Gene expression profiles of mouse embryonic stem cell derived macrophages infected with Salmonella typhimurium |
1.9 | | Chst12 | 'chemical hypoxia' vs 'control' | growth condition | Comparison of gene expression in whole blood of mice subjected to chemical hypoxia in vivo. |
1.9 | | Chst12 | 'P60; insulin-expressing mature beta cells' vs 'E16.5; insulin-expressing nascent beta cells' | age, cell type | Transcriptional profiling of nascent and mature pancreatic beta cells |
-1.8 | | Chst12 | 'CpG; 6 hour' vs 'none; 0 hour' in 'none' | RNA interference, stimulus, time | RNA-seq of Control and SMRT KD CD8α+ DCs at 0hr and 6hr CpG stimulation |
1.8 | | Chst12 | '10 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
-1.8 | | Chst12 | '19BL; differentiated 3factor-reprogrammed induced pluripotent stem cell' vs 'R1; differentiated embryonic stem cell' at '11 day' | cell line, growth condition, time | Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines |
-1.7 | | Chst12 | 'Ifnar1 knockout' vs 'wild type genotype' in 'specific pathogen free C57BL/6' | genotype, strain | RNA sequencing of primary isolated unstimulated murine splenic cDC from specific pathogen free (SPF), Germ Free (GF) and Interferon alpha/beta receptor 1 (Ifnar) knock out mice. |
-1.7 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter and SGC-CBP30; 10 nanogram per milliliter' vs 'none' in 'primary cell line; wild type genotype' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
1.7 | | Chst12 | 'granulocyte' vs 'hemopoietic stem cell' | cell type | Gene expression data from mouse hemopoietic stem cells (LSKs), promyelocytes, myelocytes and granulocytes. |
1.7 | | Chst12 | 'myelocyte' vs 'hemopoietic stem cell' | cell type | Gene expression data from mouse hemopoietic stem cells (LSKs), promyelocytes, myelocytes and granulocytes. |
1.7 | | Chst12 | 'AZD5069; 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
-1.7 | | Chst12 | 'Influenza A virus (A/Puerto Rico/8/1934(H1N1)); 2 day' vs 'mock' in 'A/J' | infect, strain, time | Genomic profiling of collaborative cross founder mouse strains infected with respiratory viruses to discover novel transcripts and infection-related strain-specific gene and isoform expression |
1.6 | | Chst12 | 'Irx3 knockout' vs 'control' at '7 day' | genetic modification, time | RNA-Seq of mouse Irx3-KO and Control ME3 cells on days 1 and 7 of adipogenic differentiation |
1.6 | | Chst12 | 'Drosha -/-' vs 'wild type genotype' | genotype | RNA-seq of mouse ES cells with conditional Drosha knockout against wild type controls to identify pri-miRNAs |
1.6 | | Chst12 | '3 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn0' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
1.5 | | Chst12 | 'neuron' vs 'differentiating progenitor' | cell type | Transcription profiling by high throughput sequencing of proliferating neural stem cells, differentiating neurogenic progenitors and newborn neurons using a dual-reporter mouse line |
-1.5 | | Chst12 | 'MG132; 1 micromolar' vs 'DMSO' in 'CHOP-/-' | compound, genotype | Microarray to find CHOP dependent genes in response to proteasome inhibition |
-1.5 | | Chst12 | 'Salmonella enterica serovar Typhimurium' vs 'control' in 'derived macrophage from E14 cell line' | clinical information, infect | Gene expression profiles of mouse embryonic stem cell derived macrophages infected with Salmonella typhimurium |
-1.4 | | Chst12 | "tunicamycin; 2 microgram per milliliter" vs "DMSO" in "PWK/PhJ" | compound, strain | Transcription profiling by high throughput sequencing of mouse embryonic fibroblasts treated with tunicamycin to study the transcriptional response to endoplasmic reticulum stress |
1.4 | | Chst12 | 'human-Mfn2 T111A/S442A-overexpressing (Mfn2AA)' vs 'wild type' in '5 week; left ventricle' | age, genotype, organism part | Transcription profiling by high throughput sequencing of a mitofusin 2 (Mfn2) mutant in mouse |
1.4 | | Chst12 | '6 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
1.4 | | Chst12 | 'trichostatin A and LIF' at '12 hour' vs 'none' at '0 hour' | compound, time | Transcription profiling of mouse embryonic stem cell line CGR8 grown in presence of Leukemia Inhibitory Factor and treated with trichostatin A |
-1.4 | | Chst12 | 'macrophage; lipopolysaccharide stimulated' vs 'macrophage; unstimulated' | cell type, treatment | Gene expression profile of GM-CSF derived bone marrow dendritic cell subsets after LPS stimulation |
-1.4 | | Chst12 | 'normobaric hypoxia' vs 'control' | growth condition | Comparison of gene expression in whole blood of mice subjected to normobaric hypoxia in vivo. |
-1.4 | | Chst12 | 'renin-expression' vs 'control' | phenotype | Expression data from mouse bone marrow cells expressing renin driven expression of green fluorescent protein. |
1.4 | | Chst12 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
1.4 | | Chst12 | 'carotid body' vs 'adrenal medulla' | organism part | Expression profile of mouse carotid body and adrenal medulla [RNA-Seq] |
-1.4 | | Chst12 | 'extracellular vesicle; EMT cell culture medium' vs 'none' | sampling site, stimulus | Cellular and extracellular vesicle RNA sequence for E-cadherin-RFP EMT reporter system expressing mouse breast cancer cell line Py2T during EMT/MET |
1.4 | | Chst12 | 'ulcer' vs 'distant normal tissue' in 'Bmp4 overexpression' | genotype, sampling site, time | Intestinal ulcers from biopsy-wounded wild-type and Bmp4-overexpressing mice |
-1.3 | | Chst12 | 'MG132; 1 micromolar' vs 'DMSO' in 'ATF5 knockdown' | compound, genotype | Microarray to find ATF5 dependent genes in response to proteasome inhibition |
1.3 | | Chst12 | '7 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
-1.3 | | Chst12 | 'mutant MyoD expression' at '24 hour' vs 'wild type MyoD expression' at '0 hour' | phenotype, time | Transcription profiling of mouse embryoic fibroblasts expressing wild type MyoD or its non-acetylatable version MyoD RRR to investigate how MyoD acetylation may contribute to differential gene activation. |
-1.3 | | Chst12 | '3D culture' vs '2D culture' | growth condition | mRNA-seq of mouse salivary gland cancer cells cultured in adherent or non-adherent culture |
1.3 | | Chst12 | 'human-Mfn2 T111A/S442A-overexpressing (Mfn2AA)' vs 'tet-off control' in '5 week; left ventricle' | age, genotype, organism part | Transcription profiling by high throughput sequencing of a mitofusin 2 (Mfn2) mutant in mouse |
1.3 | | Chst12 | 'transplanted secondary tumors' vs 'normal' in 'kidney' | clinical information, organism part | Premature termination of in vivo reprogramming leads to cancer development through altered epigenetic regulation [array] |
-1.3 | | Chst12 | 'neurosphere in differentiation medium; 1 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
1.3 | | Chst12 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'proerythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
1.3 | | Chst12 | 'liver-specific Cnot1 knockout' vs 'wild type' | phenotype | Roles of mRNA decay in liver development |
-1.3 | | Chst12 | 'status epilepticus' vs 'none' in 'astrocyte; soticlestat; 30 milligram per kilogram' | cell type, compound, disease | RNA-seq profiling of three distinct cell populations in a murine model of epilepsia with and without drug treatment |
-1.3 | | Chst12 | 'extensive self renewing erythroblast' vs 'restrictive self renewing erythroblast' | cell type | Restrictive and extensively self-renewing erythroblast |
-1.2 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar' vs 'none' in 'primary cell line; MEF2C/D knockout' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-1.2 | | Chst12 | 'doxycycline-induced expression of NGN3' vs 'control' at '48 hour' | time, treatment | Transcription profiling by array of mouse embryonic stem cells expressing the transcription factor NGN3 for 12 hours, 24 hours and 48 hours |
-1.2 | | Chst12 | 'anti-CD3/anti-CD28' vs 'none' in 'FOXP3 overexpression' | genotype, stimulus | Transcription profiling by array of FOXP3 overexpression in resting and activated mouse CD4+ T cells |
-1.2 | | Chst12 | 'seizure-preconditioning followed by intra-amygdala kainic acid' vs 'sham-preconditioning followed by intra-amygdala vehicle' | clinical treatment | Transcription profiling by array of mice with epileptic tolerance |
-1.2 | | Chst12 | '5,9-endoperoxy-cholest-7-en-3β,6α-diol' vs 'vehicle (cyclodextrin)' | compound, time | Array results for differential gene expression in 661W, a mouse cone photoreceptor-derived cell line, comparing cells incubated with vehicle controls vs. those treated with either of two 7-dehdyrocholesterol-derived oxysterols or cholesterol |
1.2 | | Chst12 | 'Alb-Cre-ERT2 / Cnot1 flox/flox' vs 'Cnot1 flox/flox' in 'none' | compound, genotype, time | RNA-seq of livers in control and Cnot1 tamoxifen-inducible liver-specific knockout mice |
-1.2 | | Chst12 | 'Staphylococcus aureus Sanger476; 2 hour' vs 'none; 0 hour' in 'C57BL/6J' | infect, strain, time | Gene Expression-Based Classifiers Identify Staphylococcus aureus Infection in Mice and Humans |
-1.2 | | Chst12 | 'mir181a1/b1 Knockout' vs 'wild type' | genotype | Mouse CD4+/CD8+ thymocytes from miR-181a1/b1 KO vs WT |
1.2 | | Chst12 | 'Zbtb10 knockdown' vs 'control' at '6 hour' | genotype, time | RNA-seq of Zbtb10 Knockdown and Control cDC1 dendritic cells (Cd8+) |
1.2 | | Chst12 | 'AhCre Cited1 knockout' vs 'control' | genotype | Cited-1 deficiency suppresses intestinal tumorigenesis through the repression of the Wnt pathway- evidence for the just right model of Wnt mediated tumorigenesis |
1.2 | | Chst12 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'mix of orthochromatic and polychromatophilic erythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
1.2 | | Chst12 | 'high fat diet; 30 degree celsius' vs 'chow; 23 degree celsius' in 'white adipose tissue' | diet, organism part, temperature | RNA-seq of brown and white mouse adipose tissue at thermoneutrality and high-fat diet |
-1.2 | | Chst12 | 'neural stem cell' vs 'niche cell' | cell type | Transcription profiling by high throughput sequencing of three populations of primary dentate gyrus cells |
1.1 | | Chst12 | 'doxorubicin; 17.5 milligram per kilogram body weight' vs 'vehicle' in 'scramble; podocyte' | cell type, compound, genotype | Transcription profiling to identify the role of MOF in primary MEFs and differentiated podocytes in response to Adriamycin |
-1.1 | | Chst12 | 'lipopolysaccharide; 10 nanogram per milliliter' vs 'none' in 'primary cell line; MEF2C/D knockout' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-1.1 | | Chst12 | '90 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
-1.1 | | Chst12 | '180 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
-1.1 | | Chst12 | '21 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
-1.1 | | Chst12 | '730 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
-1.1 | | Chst12 | '365 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
-1.1 | | Chst12 | 'anti-CD3/anti-CD28' vs 'none' in 'empty vector' | genotype, stimulus | Transcription profiling by array of FOXP3 overexpression in resting and activated mouse CD4+ T cells |
1.1 | | Chst12 | 'N-acetylcysteine; 1 day differentiated; 1 millimolar' vs 'none; 1 day differentiated' | compound, developmental stage | RNA-seq of C17.2 neuronal progenitor cells exposed to cerium oxide nanoparticles during cell differentiation |
-1.1 | | Chst12 | 'extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
1.1 | | Chst12 | 'trichostatin A and LIF' at '6 hour' vs 'none' at '0 hour' | compound, time | Transcription profiling of mouse embryonic stem cell line CGR8 grown in presence of Leukemia Inhibitory Factor and treated with trichostatin A |
-1.1 | | Chst12 | '7-ketocholesterol' vs 'vehicle (cyclodextrin)' | compound, time | Array results for differential gene expression in 661W, a mouse cone photoreceptor-derived cell line, comparing cells incubated with vehicle controls vs. those treated with either of two 7-dehdyrocholesterol-derived oxysterols or cholesterol |
-1.1 | | Chst12 | 'Porphyromonas gingivalis; hyperlipidemia' vs 'normal' | infect, phenotype | hyperlipidemia impaired innate response |
1.1 | | Chst12 | "muscularis externa layer of small intestine" vs "lamina propria of small intestine" in "YFP positive" | organism part, phenotype | Bulk RNA-sequencing of self-maintaining versus monocyte-replaced gut macrophages |
1.1 | | Chst12 | 'infarct and border region of left ventricle 5 days post-myocardial infarction; C57BL/6J' vs 'left ventricle at baseline (no myocardial infarction) in the same region as the infarct in post-myocardial infarction hearts; C57BL/6J' | clinical information, strain | Expression data from C57BL/6J and MRL/MpJ hearts following acute myocardial infarction |
-1.1 | | Chst12 | 'recombinant human interleukin-2; 100 unit per milliliter; 6 hour' vs 'control; 0 hour' | compound, time | Transcription profiling by array of mouse CTLL-2 cell line treated with recombinant human interleukin-2 |
1.1 | | Chst12 | 'Pkhd1Cre; Pkd2 F/F' vs 'wild type' | genotype | Next Generation Sequencing of PKD2 mutant mice kidneys |
-1.1 | | Chst12 | 'tamoxifen induction at 2 months, wait 3 months' vs 'no tamoxifen induction' in 'basal cell of prostate epithelium; CK5-CreERT2 transgenic line' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
-1.1 | | Chst12 | 'stabilization-competent' vs 'stabilization-incompetent' in '23 day; secondary reprogramming cell' | age, cell type, phenotype | Transcription profiling by high throughput sequencing in gene expresion profile of 4 SC clones and 4 SI clones at different time points defined a stabilization competency signiture |
1.1 | | Chst12 | 'PTEN null, P53-/-' vs 'wild type genotype' | genotype | RNA seq of prostate gland from WT, PTEN pc -/- and PTEN pc-/-;P53 -/- mice |
1.1 | | Chst12 | 'soticlestat; 30 milligram per kilogram' vs 'none' in 'astrocyte; none' | cell type, compound, disease | RNA-seq profiling of three distinct cell populations in a murine model of epilepsia with and without drug treatment |
1 | | Chst12 | 'postnatal day 60' vs 'postnatal day 1' in 'insulin-expressing immature beta cell' | cell type, developmental stage | Transcription profiling by high throughput sequencing of murine beta cells at key stages of maturation |
-1 | | Chst12 | '6 hour' vs '3 hour' in 'fetal bovine serum; 10 percent' | growth condition, time | Transcriptomic changes in C3H10T1/2 cells exposed to lipid deprivation |
-1 | | Chst12 | '5 week' vs '1 week' in 'Jak2+/V617F; CRISPR/Cas9 mediated knockout of Dnmt3a' | genotype, time | RNA-seq of Jak2VF LSK cells transduced with Dnmt3a-Cas9-GFP lentivirus vs. emp-Cas9-GFP controls one week and five weeks post methylcellulose plating |
-1 | | Chst12 | '14 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
-1 | | Chst12 | 'MG132; 1 micromolar' vs 'DMSO' in 'wild type' | compound, genotype | Microarray to find ATF5 dependent genes in response to proteasome inhibition |
-1 | | Chst12 | '60 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
-1 | | Chst12 | '30 day' vs '1 day' | age | Transcriptional profilling of female mice liver as a function of age |
1 | | Chst12 | 'NrlGFP positive' vs 'NrlGFP negative' | phenotype | Transcription profiling by array of photoreceptor precursor cells selected via cell surface antigen expression. |
-1 | | Chst12 | 'mutant MyoD expression' at '12 hour' vs 'wild type MyoD expression' at '0 hour' | phenotype, time | Transcription profiling of mouse embryoic fibroblasts expressing wild type MyoD or its non-acetylatable version MyoD RRR to investigate how MyoD acetylation may contribute to differential gene activation. |
-1 | | Chst12 | 'hematopoietic stem cell and hematopoietic multipotent progenitor cell' vs 'common myeloid progenitor' | cell type | Transcription profiling by high throughput sequencing between multipotent hematopoietic stem progenitor cells LS+K) and myeloid committed cells (LS−K) of the mouse bone marrow |
-1 | | Chst12 | 'lipopolysaccharide; 100 nanogram per milliliter and interferon gamma 20 nanogram per milliliter' vs 'none' | stimulus | Transcriptional profiling in macrophages in stimulated and unstimulated conditions. |
-1 | | Chst12 | 'spontaneous lung tumor' vs 'normal' | disease state, disease | Transcription profiling by array of spontaneous lung tumors in mice to compare to human non-small cell lung cancer |
-1 | | Chst12 | 'Porphyromonas gingivalis; normal' vs 'normal' | infect, phenotype | hyperlipidemia impaired innate response |
-1 | | Chst12 | 'doxycycline; 200 nanogram per milliliter; neoplasm; 5 day' vs 'none; normal; 0 day' | compound, phenotype, time | RNA-seq of doxycycline induced tumor and residual mouse primary mammary epithelial cells grown in 3D cell cultures against non-induced controls |
1 | | Chst12 | 'XBP1s overexpression' vs 'wild type genotype' in 'none' | compound, genotype | Overexpression of spliced XBP1 in in vitro Th2 cells, and comparison to 4u8c treatment |
-1 | | Chst12 | 'oxygen/glucose-deprivation followed by restoration of oxygen/glucose' vs 'none' in 'wild type genotype; undifferentiated' | genotype, growth condition, stimulus | SUMOylation promotes survival and integration of neural stem cell grafts in stroke |
1 | | Chst12 | 'synovial sarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-1 | | Chst12 | '500 micromolar palmitate' vs '1 volume percent bovine serum albumin' | compound | Transcription profiling of mouse C2C12 myotubes treated overnight with 500 uM palmitate or 1% bovine serum albumin control to identify mediators of obesity-linked reductions in PGC-1 |
-1 | | Chst12 | 'recombinant human interleukin-2; 100 unit per milliliter; 12 hour' vs 'control; 0 hour' | compound, time | Transcription profiling by array of mouse CTLL-2 cell line treated with recombinant human interleukin-2 |
-1 | | Chst12 | 'recombinant human interleukin-2; 100 unit per milliliter; 10 hour' vs 'control; 0 hour' | compound, time | Transcription profiling by array of mouse CTLL-2 cell line treated with recombinant human interleukin-2 |
-1 | | Chst12 | 'V6.5; embryonic stem cell’ vs 'wild type; endothelial' | cell line, cell type, genotype | CD47 Inhibits Self-renewal and Reprogramming by Regulating c-Myc and Other Stem Cell Transcription Factors |
-1 | | Chst12 | "tunicamycin; 2 microgram per milliliter" vs "DMSO" in "A/J" | compound, strain | Transcription profiling by high throughput sequencing of mouse embryonic fibroblasts treated with tunicamycin to study the transcriptional response to endoplasmic reticulum stress |
-1 | | Chst12 | 'E2f8 knock-out' vs 'wild type' | genotype | Expression data from WT, E2f8 KO, Rb KO and Rb;E2f8 DKO spleen Ter19+CD71high sorted cells |
1 | | Chst12 | 'infarct and border region of left ventricle 5 days post-myocardial infarction; MRL/MpJ' vs 'left ventricle at baseline (no myocardial infarction) in the same region as the infarct in post-myocardial infarction hearts; MRL/MpJ' | clinical information, strain | Expression data from C57BL/6J and MRL/MpJ hearts following acute myocardial infarction |
1 | | Chst12 | 'conditional Kras and p53 mutation induced soft tissue sarcoma' vs 'normal' | disease | Transcription profiling by array of mouse soft tissue sarcoma samples induced by conditional mutations of Kras and p53 against healthy muscles from mice of the same genotype but no induced sarcoma |
-1 | | Chst12 | 'recombinant human interleukin-2; 100 unit per milliliter; 16 hour' vs 'control; 0 hour' | compound, time | Transcription profiling by array of mouse CTLL-2 cell line treated with recombinant human interleukin-2 |
-1 | | Chst12 | 'Tet2 knockout' vs 'wild type' in 'hematopoietic progenitor cell' | cell type, genotype | Transcription profiling by high throughput sequencing of bone marrow stem and progenitor cells from Tet2 depleted mice |
1 | | Chst12 | '70 week' vs '6 week' in 'none; none; | age, irradiate | Pericyte induced reprogramming of the bone marrow microenvironment drives stem and cancer cell quiescence |
-1 | | Chst12 | 'transgenic' vs 'wild type' in '133 day; C57BL/6' | age, genotype, strain | Whole genome transcriptome analysis identifies indices of fast and slow disease progression in two ALS mouse models |
-1 | | Chst12 | 'P19; transduced with MyoD lentivirus' vs 'P19; control' | cell line, treatment | Genetic and epigenetic determinants of neurogenesis and myogenesis [expression profiling] |
1 | | Chst12 | 'AZD7507; AZD5069 (at same dosage); 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
